Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Beam Therapeutics Q2 2024 GAAP EPS $(1.11) Beats $(1.25) Estimate, Sales $11.772M Miss $14.183M Estimate

Author: Benzinga Newsdesk | August 06, 2024 06:39am
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1.25) by 11.2 percent. This is a 2.78 percent decrease over losses of $(1.08) per share from the same period last year. The company reported quarterly sales of $11.772 million which missed the analyst consensus estimate of $14.183 million by 17.00 percent. This is a 41.48 percent decrease over sales of $20.116 million the same period last year.

Posted In: BEAM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist